ARVINAS INC (ARVN) Stock Fundamental Analysis

NASDAQ:ARVN • US04335A1051

11.77 USD
+0.33 (+2.88%)
Last: Feb 18, 2026, 02:33 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ARVN. ARVN was compared to 191 industry peers in the Pharmaceuticals industry. The financial health of ARVN is average, but there are quite some concerns on its profitability. While showing a medium growth rate, ARVN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ARVN had negative earnings in the past year.
  • In the past year ARVN has reported a negative cash flow from operations.
  • ARVN had negative earnings in each of the past 5 years.
  • In the past 5 years ARVN reported 4 times negative operating cash flow.
ARVN Yearly Net Income VS EBIT VS OCF VS FCFARVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

  • ARVN has a Return On Assets of -6.92%. This is in the better half of the industry: ARVN outperforms 71.20% of its industry peers.
  • With a decent Return On Equity value of -10.35%, ARVN is doing good in the industry, outperforming 73.82% of the companies in the same industry.
Industry RankSector Rank
ROA -6.92%
ROE -10.35%
ROIC N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ARVN Yearly ROA, ROE, ROICARVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K

1.3 Margins

  • ARVN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARVN Yearly Profit, Operating, Gross MarginsARVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ARVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ARVN has been increased compared to 1 year ago.
  • ARVN has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ARVN has an improved debt to assets ratio.
ARVN Yearly Shares OutstandingARVN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARVN Yearly Total Debt VS Total AssetsARVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of -0.05, we must say that ARVN is in the distress zone and has some risk of bankruptcy.
  • ARVN has a Altman-Z score of -0.05. This is comparable to the rest of the industry: ARVN outperforms 48.69% of its industry peers.
  • ARVN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ARVN (0.00) is better than 62.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.05
ROIC/WACCN/A
WACC9.22%
ARVN Yearly LT Debt VS Equity VS FCFARVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 5.70 indicates that ARVN has no problem at all paying its short term obligations.
  • ARVN has a better Current ratio (5.70) than 66.49% of its industry peers.
  • A Quick Ratio of 5.70 indicates that ARVN has no problem at all paying its short term obligations.
  • ARVN's Quick ratio of 5.70 is fine compared to the rest of the industry. ARVN outperforms 67.54% of its industry peers.
Industry RankSector Rank
Current Ratio 5.7
Quick Ratio 5.7
ARVN Yearly Current Assets VS Current LiabilitesARVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ARVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.66%, which is quite impressive.
  • The Revenue has grown by 10.47% in the past year. This is quite good.
  • ARVN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 43.69% yearly.
EPS 1Y (TTM)82.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
Revenue 1Y (TTM)10.47%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-59.08%

3.2 Future

  • Based on estimates for the next years, ARVN will show a small growth in Earnings Per Share. The EPS will grow by 7.09% on average per year.
  • The Revenue is expected to decrease by -4.14% on average over the next years.
EPS Next Y72.55%
EPS Next 2Y-3.61%
EPS Next 3Y-3.22%
EPS Next 5Y7.09%
Revenue Next Year9.15%
Revenue Next 2Y-41.21%
Revenue Next 3Y-29.48%
Revenue Next 5Y-4.14%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ARVN Yearly Revenue VS EstimatesARVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ARVN Yearly EPS VS EstimatesARVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARVN. In the last year negative earnings were reported.
  • Also next year ARVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARVN Price Earnings VS Forward Price EarningsARVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARVN Per share dataARVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

  • ARVN's earnings are expected to decrease with -3.22% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.61%
EPS Next 3Y-3.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ARVN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARVINAS INC

NASDAQ:ARVN (2/18/2026, 2:33:04 PM)

11.77

+0.33 (+2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05
Earnings (Next)03-02
Inst Owners96.53%
Inst Owner Change-11.61%
Ins Owners2.5%
Ins Owner Change0.36%
Market Cap755.87M
Revenue(TTM)312.30M
Net Income(TTM)-58.40M
Analysts76.15
Price Target13.5 (14.7%)
Short Float %7.21%
Short Ratio5.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.38%
Min EPS beat(2)18.03%
Max EPS beat(2)40.73%
EPS beat(4)4
Avg EPS beat(4)79.1%
Min EPS beat(4)18.03%
Max EPS beat(4)218.09%
EPS beat(8)7
Avg EPS beat(8)41.08%
EPS beat(12)9
Avg EPS beat(12)29.09%
EPS beat(16)9
Avg EPS beat(16)16.23%
Revenue beat(2)1
Avg Revenue beat(2)23.18%
Min Revenue beat(2)-27.7%
Max Revenue beat(2)74.06%
Revenue beat(4)2
Avg Revenue beat(4)95.07%
Min Revenue beat(4)-27.7%
Max Revenue beat(4)345.02%
Revenue beat(8)4
Avg Revenue beat(8)34.48%
Revenue beat(12)7
Avg Revenue beat(12)34.53%
Revenue beat(16)10
Avg Revenue beat(16)34.32%
PT rev (1m)2.27%
PT rev (3m)6.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.96%
EPS NY rev (1m)0%
EPS NY rev (3m)38.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.42
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-5.13
FCFYN/A
OCF(TTM)-5.1
OCFYN/A
SpS4.86
BVpS8.79
TBVpS8.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -6.92%
ROE -10.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-22.88%
ROA(5y)-19.47%
ROE(3y)-47.02%
ROE(5y)-36.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.82%
Cap/Sales 0.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.7
Quick Ratio 5.7
Altman-Z -0.05
F-Score6
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)69.16%
Cap/Depr(5y)101.08%
Cap/Sales(3y)3.18%
Cap/Sales(5y)9.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.41%
EPS Next Y72.55%
EPS Next 2Y-3.61%
EPS Next 3Y-3.22%
EPS Next 5Y7.09%
Revenue 1Y (TTM)10.47%
Revenue growth 3Y78.01%
Revenue growth 5Y43.69%
Sales Q2Q%-59.08%
Revenue Next Year9.15%
Revenue Next 2Y-41.21%
Revenue Next 3Y-29.48%
Revenue Next 5Y-4.14%
EBIT growth 1Y82.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.25%
EBIT Next 3Y8.93%
EBIT Next 5YN/A
FCF growth 1Y3.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.53%
OCF growth 3YN/A
OCF growth 5YN/A

ARVINAS INC / ARVN FAQ

What is the ChartMill fundamental rating of ARVINAS INC (ARVN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ARVN.


Can you provide the valuation status for ARVINAS INC?

ChartMill assigns a valuation rating of 0 / 10 to ARVINAS INC (ARVN). This can be considered as Overvalued.


Can you provide the profitability details for ARVINAS INC?

ARVINAS INC (ARVN) has a profitability rating of 1 / 10.


What is the expected EPS growth for ARVINAS INC (ARVN) stock?

The Earnings per Share (EPS) of ARVINAS INC (ARVN) is expected to grow by 72.55% in the next year.